Literature DB >> 23247607

[Acne inversa (hidradenitis suppurativa). From diagnosis to therapy].

M Mühlstädt1, F G Bechara, C Kunte.   

Abstract

An estimated 1% of the population suffers from hidradenitis suppurativa/acne inversa, a chronic inflammatory disease that is a burden for patients and doctors alike. The progressive disease often isolates the patients socially and causes constant pain. It can take years until the diagnosis is finally made. Dermatologists are often confronted with a relapsing condition and a frustrated patient. This article summarizes our understanding of the disease and outlines therapeutic options.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23247607     DOI: 10.1007/s00105-012-2479-8

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  22 in total

1.  Clindamycin and rifampicin combination therapy for hidradenitis suppurativa.

Authors:  C O Mendonça; C E M Griffiths
Journal:  Br J Dermatol       Date:  2006-05       Impact factor: 9.302

Review 2.  A systematic review of treatments for hidradenitis suppurativa.

Authors:  Pranita V Rambhatla; Henry W Lim; Iltefat Hamzavi
Journal:  Arch Dermatol       Date:  2011-12-19

3.  [Acne inversa].

Authors:  F G Bechara; W Hartschuh
Journal:  Hautarzt       Date:  2010-01       Impact factor: 0.751

Review 4.  Pathogenesis and pharmacotherapy of Hidradenitis suppurativa.

Authors:  Maiwand Nazary; H H van der Zee; E P Prens; Gert Folkerts; Jurr Boer
Journal:  Eur J Pharmacol       Date:  2011-09-14       Impact factor: 4.432

5.  Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa.

Authors:  S Kamp; A M Fiehn; K Stenderup; C Rosada; B Pakkenberg; K Kemp; T N Dam; G B Jemec
Journal:  Br J Dermatol       Date:  2011-05       Impact factor: 9.302

6.  Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β.

Authors:  H H van der Zee; L de Ruiter; D G van den Broecke; W A Dik; J D Laman; E P Prens
Journal:  Br J Dermatol       Date:  2011-05-17       Impact factor: 9.302

7.  Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients.

Authors:  G Gener; F Canoui-Poitrine; J E Revuz; O Faye; F Poli; G Gabison; F Pouget; C Viallette; P Wolkenstein; S Bastuji-Garin
Journal:  Dermatology       Date:  2009-07-08       Impact factor: 5.366

8.  Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies.

Authors:  Jean E Revuz; Florence Canoui-Poitrine; Pierre Wolkenstein; Cedric Viallette; Germaine Gabison; Florence Pouget; Florence Poli; Ousmane Faye; Jean Claude Roujeau; Genevieve Bonnelye; Jean Jacques Grob; Sylvie Bastuji-Garin
Journal:  J Am Acad Dermatol       Date:  2008-10       Impact factor: 11.527

9.  Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa.

Authors:  G B Jemec; P Wendelboe
Journal:  J Am Acad Dermatol       Date:  1998-12       Impact factor: 11.527

10.  Increased prevalence of metabolic syndrome in patients with acne inversa.

Authors:  Robert Sabat; Akewit Chanwangpong; Sylke Schneider-Burrus; Deborah Metternich; Georgios Kokolakis; Agata Kurek; Sandra Philipp; Daniela Uribe; Kerstin Wolk; Wolfram Sterry
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

View more
  1 in total

Review 1.  [Hidradenitis suppurativa/acne inversa: An update].

Authors:  J Kirschke; S Hessam; F G Bechara
Journal:  Hautarzt       Date:  2015-06       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.